GIBSON DUNN

Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen

Firm News | March 3, 2026

Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc. The all-stock transaction is valued at approximately $300 million.

Our corporate team includes partners Branden Berns and Ryan Murr and associates Evan Shepherd, Lauren Navarro, Hunter Michielson, and Lauren Romagnoli. Partners Pamela Lawrence Endreny and Rachel Kleinberg and associate Elizabeth Johnson are advising on tax aspects, partner Bradley Smith is advising on antitrust aspects, partner David Wolber is advising on international trade aspects, and partner Sean Feller is advising on benefits.

Related People

Branden C. Berns

Ryan A. Murr

Evan Shepherd

Lauren Navarro

Hunter Michielson

Lauren Romagnoli

Pamela Lawrence Endreny

Rachel D. Kleinberg

Bradley P. Smith

David A. Wolber

Sean C. Feller

Related Capabilities

Life Sciences

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**